Intas has secured a distributor for its ranibizumab biosimilar throughout select countries in the Middle East, while Phase III trials continue ahead of anticipated US approval.
Intas Pharmaceuticals Ltd. has signed an exclusive license and supply agreement with Axantia Holding to distribute its biosimilar to Genentech’s Lucentis (ranibizumab) throughout certain Middle Eastern territories, including Saudi Arabia, Jordan, Iraq, Lebanon and GCC countries.
Axantia will register, hold the marketing authorization for and commercialize Intas’ ranibizumab throughout these territories through its pharmaceutical subsidiaries, Pharma...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
